JPRN-UMIN000029205
Completed
N/A
Effects of Dapagliflozin, a SGLT2 inhibitor, on Body Composition in Japanese Type 2 Diabetes Patients without severe Obesity - Effects of Dapagliflozin on Body Composition
Jinnouchi Hispital0 sites60 target enrollmentDecember 31, 2017
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Jinnouchi Hispital
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •severe obesity (BMI\>35\) Type 1 DM ketoacidosis unstable clinical conditions active infection, liver disease, cancer eGFR\<45
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424NL-OMON48616Radboud Universitair Medisch Centrum15
Active, Not Recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-001569-17-NLRadboud university medical center15
Active, Not Recruiting
N/A
Impact of treatment with Dapagliflozin in type 1 diabetic patientsEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
Not Yet Recruiting
N/A
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
Recruiting
N/A
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.JPRN-UMIN000025454Dokkyo Medical University Department of Endocrinology and Metabolism20